


Express Mail Label: EV05807487
Date of Deposit: February 19, 2002

02-21-02

3700 #4 0420
ney Docket No.: 17999-001DIY 2-19-02



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : DeGroot

SERIAL NUMBER : 10/055,524

FILING DATE : October 26, 2001

FOR : HIV Vaccine Candidate Peptides

EXAMINER : Not Yet Assigned

ART UNIT :

RECEIVED
APR 04 2002

TECH CENTER 1600/2900

RECEIVED
MAY 01 2002
TECH CENTER 1600/2900

BOX IDS

Commissioner for Patents
Washington, D.C. 20231



30623

PATENT TRADEMARK OFFICE

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Information Disclosure Statement (2 pages);
2. Modified Form 1449/PTO (1 page), in duplicate; and
3. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any additional fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 17999-001 DIV. A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Christina V. Karnakos, Reg. No. 45,899
for Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicant
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: February 19, 2002

TRA 1632154v1

Express Mail Label No.: EV0 4877US
Date of Deposit: February 19, 2002

Attorney Docket No. 17999-001 DIV

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: DeGroot
SERIAL NUMBER: 10/055,524 EXAMINER: Not Yet Assigned
FILING DATE: October 26, 2001 ART UNIT:
FOR: HIV Vaccine Candidate Peptides

BOX IDS

Commissioner for Patents
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicant hereby makes of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is believed required.

A copy of each of the references in the above-identified application is enclosed unless otherwise indicated on the attached modified Form PTO-1449. It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.



RECEIVED

APR 04 2002

TECH CENTER 1600/2900

TECH CENTER 1600/2900

MAY 01 2002


RECEIVED

APPLICANTS: DeGroot
U.S.S.N.: 10/055,524

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 17999-001 DIV.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Attorney for Applicant
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Reg. No.
45,899

Dated: February 19, 2002

TRA 1632140v1

Express Mail Label No.: EV05 4877US
Date of Deposit: February 19, 2002



Modified Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Serial Number	10/055,524
Filing Date	October 26, 2001
First Named Inventor	De Groot
Group Art Unit	
Examiner Name	Not Yet Assigned
Attorney Docket Number	17999-001DIV (BURF-1990)

TECH CENTER 1600/2900

APR 04 2002

RECEIVED

U.S. PATENT DOCUMENTS

Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1*	5,886,320	03/23/99	Gallo, et al.			09/03/96
	A2*	5,876,731	03/2/99	Sia, et al.			06/05/95
	A3*	5,817,318	10/06/98	Sia, et al.			06/06/95

FOREIGN PATENT DOCUMENTS

Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No

OTHER NON-PATENT LITERATURE DOCUMENTS

Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	B1*	Germain & Margulies (1993). "The biochemistry and cell biology of antigen processing and presentation" <i>Ann. Rev. Immunol.</i> 11: 403-450.
	B2*	Falk, et al. (1991). "Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules" <i>Nature</i> 351: 290-296.
	B3*	Wilson, et al. (1998). "Cross-clade envelope glycoprotein 160-specific CD8+ cytotoxic T lymphocyte responses in early HIV type 1 clade B infection" <i>AIDS Res. Hum. Retroviruses</i> 14: 925-937.
	B4*	McAdam, et al. (1998). "Cross-clade recognition of p55 by cytotoxic T lymphocytes in HIV-1 infection" <i>AIDS</i> 12: 571-579.
	B5*	Lynch, et al. (1998). "Cross-clade cytotoxic T cell response to Human Immunodeficiency Virus type 1 proteins among HLA disparate North Americans and Thais" <i>J Infect Dis.</i> 178: 1040-1046.
	B6*	Boyer, et al. (1998). "HIV-1 DNA based vaccine induces a CD8 mediated cross-clade CTRL response" <i>Dev. Biol. Stand.</i> 95: 147-153.
	B7*	Cao, et al. (1997). "Cytotoxic T-lymphocyte cross-reactivity among different Human Immunodeficiency Virus type 1 clades: Implications for vaccine development" <i>J. Virol.</i> 71: 8615-8623.
	B8*	Durali, et al. (1998). "Cross-reactions between the cytotoxic T-lymphocyte responses of Human Immunodeficiency Virus-infected African and European patients" <i>Virol.</i> 72: 3547-3553.
	B9*	Koup (1994). "Virus escape from CTL recognition" <i>J. Exp. Med.</i> 180: 779-782.
	B10*	Dai, et al. (1992). "Mutation of Human Immunodeficiency Virus type 1 at amino acid 585 on gp41 results in loss of killing by CD8+ A24-restricted cytotoxic T lymphocytes" <i>J. Virol.</i> 66: 3151-3154.
	B11*	Johnson, et al. (1992). "Identification of overlapping HLA class I-restricted cytotoxic T cell epitopes in a conserved region of the Human Immunodeficiency Virus type 1 envelope glycoprotein: Definition of minimum epitopes and analysis of the effects of sequence variation" <i>J. Exp. Med.</i> 175: 961-971.
	B12*	Jesdale, et al. (1997). "Matrix-based prediction of MHC-binding peptides: The EpiMatrix algorithm, reagent for HIV research" in <i>Vaccines</i> . (Cold Spring Harbor Press, Cold Spring Harbor, 1997).
	B13*	Schafer, et al. (1998). "Prediction of well-conserved HIV-1 ligands using matrix-based algorithm, EpiMatrix" <i>Vaccine</i> 16: 1-5.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 09/351,036, filed July 9, 1999, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.